Light-activated wound sterilisation prototype development

光激活伤口灭菌原型开发

• 批准号: 10070618
• 金额: $ 47.54万
• 依托单位: LIGHTOX LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10070618
• 关键词: Light; activated; wound; sterilisation; prototype

The management of wounds is a "silent epidemic" that is challenging health services worldwide. The NHS treated 3.8 million patients with a wound in 2017/18, translating to a burden of \>£8.3billion. A major factor that influences the healing of a wound is an infection by colonising microbes. Untreated infections prevent healing, but can also spread further, frequently necessitating surgery and even amputation. The increasing prevalence of contributing factors such as diabetes and obesity, and the alarming emergence of bacteria that are resistant to antibiotics means that the number of chronically infected wounds is rising in all geographies and age groups. As we face the prospect of a world where antibiotics are no longer effective, we urgently need new modalities that can lower bioburden in wounds to aid healing and, thus, lower the enormous burden faced by healthcare services. LightOx, based in Newcastle-upon-Tyne, have developed molecules that, when activated by light, cause the destruction of bacteria that colonise wounds through the generation of reactive oxygen species(ROS). We have also shown that these molecules are capable of disrupting and inhibiting the growth of biofilms -- a common complication of infected wounds that can inhibit healing. In this feasibility project, LightOx will develop our lead molecule, LightOx78, into three woundcare product prototypes -- a dressing, a hydrogel and a gel/aqueous solution -- and work with experts at Durham University to demonstrate the capability of these prototypes in the elimination of wound-colonising microbes and biofilms to aid effective wound healing. Concurrently, we will lay out an exploitation and regulatory roadmap to bring this novel technology to market as a woundcare product that augments the current standard of care. This technology could halve the average number of care appointments required to heal wounds and would have enormous benefit for health services and patients alike.

伤口管理是一种“无声的流行病”，对全世界的卫生服务构成了挑战。NHS在2017/18年度治疗了380万名伤口患者，相当于83亿英镑的负担。影响伤口愈合的一个主要因素是定植微生物的感染。未经治疗的感染阻碍了愈合，但也可能进一步传播，经常需要手术甚至截肢。糖尿病和肥胖症等致病因素的日益流行，以及对抗生素具有抗药性的细菌的惊人出现，意味着所有地区和年龄段的慢性感染伤口的数量都在上升。当我们面临抗生素不再有效的世界前景时，我们迫切需要新的方法来降低伤口中的生物负荷，以帮助愈合，从而减轻医疗服务面临的巨大负担。总部设在泰恩河畔纽卡斯尔的LightOx公司已经开发出一种分子，当被光激活时，可以通过产生活性氧物种(ROS)来摧毁定植在伤口上的细菌。我们还表明，这些分子能够破坏和抑制生物膜的生长--这是感染伤口的一种常见并发症，可能会抑制愈合。在这个可行性项目中，LightOx将把我们的铅分子LightOx78开发成三种伤口护理产品原型--敷料、水凝胶和凝胶/水溶液--并与达勒姆大学的专家合作，展示这些原型在消除伤口定植微生物和生物膜方面的能力，以帮助有效的伤口愈合。同时，我们将制定开发和监管路线图，将这项新技术作为一种提高目前护理标准的创伤护理产品推向市场。这项技术可以将治愈伤口所需的平均护理预约次数减半，并将为卫生服务和患者带来巨大好处。